Biomedical progress in therapeutics has faced significant challenges, leading to diminishing returns despite advancements in basic science, a phenomenon encapsulated by Jack Scannell's concept of Eroom's Law. This law highlights that the inflation-adjusted cost of developing new drugs has doubled approximately every nine years since the 1950s. To counter this trend, the author has been investigating structural bottlenecks in clinical trials and the FDA's role in drug testing. Initiatives like the Clinical Trial Abundance Project aim to enhance both the number and efficiency of clinical trials, arguing that faster and more informative trials can create a positive feedback loop that ultimately leads to better drug development. Critics of this approach worry that increasing the efficiency of clinical trials might compromise patient safety by allowing potentially harmful drugs to be tested more readily. However, the author contends that improving trial efficiency and developing better drug hypotheses are complementary strategies. Clinical trials should not merely serve as a validation step for existing scientific ideas; rather, they should be viewed as an active engine of discovery. Successful therapies often emerge from a cycle of trial failures, where insights gained from unsuccessful attempts inform subsequent iterations, leading to improved designs and more effective treatments. The case of CAR-T cell therapies exemplifies this dynamic process. Initially perceived as risky, CAR-T therapies have demonstrated remarkable efficacy in treating aggressive cancers like pediatric B-cell acute lymphoblastic leukemia. The FDA's accelerated approval of Kymriah, based on the promising results of the ELIANA trial, was the result of nearly two decades of clinical studies. These trials evolved through a series of failures, enabling researchers to refine their approaches and enhance the effectiveness of CAR-T treatments. By treating these trials as learning opportunities, researchers were able to uncover the complexities of T cell responses and improve the therapeutic strategies that led to CAR-T's success.